All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
On 8 October 2018, Judith Trotman a member of our Scientific Advisory Board from the Concord Repatriation General Hospital, Sydney, AU, and colleagues, published in The Lancet Oncology the secondary analysis of the GALLIUM phase III trial (NCT01332968). The GALLIUM trial evaluated the effect of first-line obinutuzumab compared to rituximab in follicular lymphoma (FL) patients. The primary analysis of the study was published in 2017 in the New England Journal of Medicine and revealed that obinutuzumab resulted in a longer progression-free survival (PFS) when compared to rituximab in previously-untreated FL patients.
The purpose of this secondary GALLIUM analysis was to assess the prognostic value of positron emission tomography-computed tomography (PET-CT) following first-line chemotherapy with either obinutuzumab or rituximab in the same FL patients. The primary endpoints of this secondary analysis were PET and CT responses at the end of the induction therapy and their association with PFS and overall survival (OS).
The results of this secondary analysis of the GALLIUM phase III trial indicated that PET is more accurate than CT in evaluating the responses of FL patients treated with first-line immunochemotherapy. The authors stated that despite the limitations of the study (retrospective nature and smaller sample size than primary analysis cohort), PET might provide a useful early prognostic marker of PFS and OS and guide response-based FL treatments.
For a video interview with the lead author Judith Trotman summarizing the key findings of this analysis during the 22nd European Hematology Association Congress (2017) click here.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox